Short bowel syndrome (SBS) is a malabsorption syndrome caused by lack of a functional small intestine. The primary symptoms of SBS are diarrhea followed by dehydration, weight loss, and malnutrition. If SBS is left untreated it can lead to kidney stones. The primary reasons behind short bowel syndrome in children are damaged intestinal tissue, blockage or obstruction in intestine, gastroschisis, and rotation of the midgut also known as malrotation and in grown-ups. Short bowel syndrome is detected in Crohn’s disease, radiation enteritis, and mesenteric ischemia. This syndrome usually occurs in cases due to surgical elimination of major portion of small intestine
Market Dynamics- Drivers
Increasing incidence of short bowel syndrome worldwide is expected to drive growth of the global short bowel syndrome market during the forecast period. According to Crohn’s & Colitis Foundation of America, in 2010 there were 10,000–20,000 people in the reported cases of short bowel syndrome, out of which 25% people suffered some or the other complication within two years of contracting the condition. The rate of absorption decreases and due of lack of sufficient nutrients to the body, many children die due to malnutrition. According to Sancilio and Company, Inc., most cases of short bowel syndrome are due to birth in congenital anomaly, in which there occurs a rotation of midgut and the child die before the age of 6 years. According to Nutrinia Ltd, the existing approach to treat infants suffering from short bowel syndrome includes proper nutritional, pharmacologic, and surgical interventions. The primary aim is to promote enteral nutrition, while curtailing the difficulties of parenteral nutrition therapy.
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/169
Most of the patients are given long-term parenteral treatment, which affects the patient and significantly increases the chances of liver disease, infections, and other complications. Babies who have substantial short bowel syndrome frequently struggle from intestinal failure-associated liver disease, bloodstream infections, and bacterial overgrowth. Furthermore, parenteral nutrition leads to a substantial economic burden on the general population and the healthcare system, with overall annual costs ranging from an estimated US$ 180,000 to US$ 570,000 and more.
GLP-2 drug class dominates the leading markets in North America and Europe
The global short bowel syndrome market is segmented on the basis of drug class and geography. On the basis of drug class, the market is divided into GLP-2, growth hormone, glutamine and others.
Increasing prescription of Gattex Therapy for Short Bowel Syndrome in North America creates a highly lucrative prospect for growth
Regional segmentation of the short bowel syndrome market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Among regions, North America accounts for the largest share in global short bowel syndrome market, owing to presence of major players and early adoption of advanced medical technologies in countries such as the U.S. and Canada. According to National Institute of Diabetes and Digestive and Kidney Disease, in 2008, there were more than 2,000 intestinal transplantations performed in the U.S., out of which 75% population was of the age group of 18-20 years. These numbers are expected to increase year on year, which would inadvertently fuel growth of the short bowel syndrome market.
Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/short-bowel-syndrome-market-169
Key players operating the short bowel syndrome market include Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, NAIA Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio & Company, Inc., Shire plc, and Zealand Pharma A/S.
Key players in the global short bowel syndrome market are focused on various growth opportunities such as product launches and approvals, in order to gain competitive edge in the market. For instance, Nutrinia Ltd. plans to begin a critical clinical trial on a drug for short bowel syndrome, which will aid thousands of patients globally by reducing their dependence on parenteral nutrition is the major cause of liver infection.
Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/169
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737